Sword Bio

Sword Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.8M

Overview

Sword Bio is a specialized bioanalytical Contract Research Organization (CRO) founded in 2020 and headquartered in San Francisco. The company leverages a team of scientists with decades of experience to offer rapid, customized assay development and testing services under various regulatory standards (non-GLP, GLP, GCP). Its core business model is providing essential laboratory services to accelerate the drug development pipelines of its biopharma clients, utilizing an 'excess capacity' operational model to ensure quick project initiation and turnaround.

DiagnosticsAI / Machine Learning

Technology Platform

Integrated suite of bioanalytical techniques including Ligand Binding Assays (LBA), qPCR/dPCR, cell-based assays, and MSD immunoassays for pharmacokinetics, immunogenicity, and biomarker analysis. Offers a 'Sword SWIFT' program for assay optimization.

Funding History

1
Total raised:$4.8M
Seed$4.8M

Opportunities

Growing demand for outsourced bioanalytical services from biopharma companies, especially in complex modalities like biologics and cell therapies.
The 'excess capacity' model addresses a key industry pain point of slow start-up times at large CROs, creating a competitive advantage in agility and speed.

Risk Factors

Revenue is project-based and susceptible to fluctuations in biotech R&D funding.
High dependence on retaining a specialized scientific workforce in a competitive talent market.
Intense competition from both large global CROs and smaller niche players.

Competitive Landscape

Operates in the highly competitive bioanalytical CRO sector, competing against large, full-service CROs (e.g., LabCorp, IQVIA) and numerous specialized boutique labs. Differentiation is based on scientific expertise, rapid project initiation ('excess capacity' model), and a flexible, partnership-driven client service approach.